Every cloud has a silver lining, and Annovis Bio (ANVS) seems to be the embodiment of this phrase in the biotechnology sector. Despite operating at a loss of $45M, the company's optimistic outlook is underpinned by a strong pipeline of drugs aimed at treating neurodegeneration. The lead product candidate, Buntanetap, has completed three Phase 1/2 clinical trials, demonstrating potential for future growth. Furthermore, ANVS405 and ANVS301 are in advanced stages of clinical trials, which could further boost the company's prospects. The stock's technicals also show promising signs. The 50-day moving average stands at $8.68, slightly below the 200-day moving average of $9.72, indicating a potential upward trend. Additionally, the stock's beta of 1.774 suggests higher volatility, which could be beneficial for risk-tolerant investors. The accumulation distribution of 57.2K and a short ratio of 1.42 further underscore the stock's potential. Wall Street's target price of $33.5 and an estimated target price of $46 reflect a bullish sentiment among analysts, with an overall consensus of 'Buy'. However, investors should be mindful of the high price-to-book ratio of 19.68 and the short percent of 0.1767. Despite the challenges, Annovis Bio's robust drug pipeline and positive technical indicators suggest it is poised for continued growth. While many millennials are steering clear of the biotech sector, it's worth taking a closer look at Annovis Bio to understand its current market trends. As anticipated, Annovis Bio is beginning to demonstrate its true potential as private investors grow increasingly confident in its future prospects. Recent fluctuations in Annovis Bio's stock price have contradicted broader market trends observed over the past few months. However, the company's uncertain fundamental indicators could suggest potential mid-term losses for private investors. Annovis Bio is set to announce its earnings today.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Annovis Bio. In general, sophisticated investors focus on analyzing Annovis Bio stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Annovis Bio's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of
Annovis Bio's intrinsic value. In addition to deriving basic predictive indicators for Annovis Bio, many experienced traders also check how macroeconomic factors affect Annovis Bio price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of Annovis Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How does Annovis Stands against Peers?
Analyzing Annovis Bio competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Annovis Bio across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
Annovis Bio Competition DetailsAnnovis Bio Gross Profit
Annovis Bio Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Annovis Bio previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Annovis Bio Gross Profit growth over the last 10 years. Please check Annovis Bio's
gross profit and other
fundamental indicators for more details.
Closer look at Annovis Bio Semi Variance
Annovis Bio has current Semi Variance of 170.66. Semi-variance provides a good measure of downside volatility for equity or a portfolio. It is similar to variance, but it only looks at periods where the returns are less than the target or average level.
Semi-variance is the square of semi-deviation.
Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.
Semi Variance | = | SUM(RET DEV)2N(ZERO) |
| = | 170.66 |
| SUM | = | Summation notation |
| RET DEV | = | Actual return deviation over selected period |
| N(ZERO) | = | Number of points with returns less than zero |
Let's now compare Annovis Bio Semi Variance to its closest peers:
| ANVS | 170.66 |
| ANAB | 19.61 |
| MRUS | 6.3 |
"Buy when there's blood in the streets," is a common adage in the investment world and it seems fitting when considering Annovis Bio (ANVS). Despite the company's operating income reflecting a loss of $45M and a net income showing a loss of $56.2M, there are signs of potential growth. The company's current ratio stands at a robust 28.11X, indicating strong financial health. Furthermore, the Wall Street target price for ANVS is $33.5, significantly higher than its 52-week high of $22.49, suggesting that analysts see substantial upside potential. Additionally, with 25.20% of shares owned by insiders, there's a strong vote of confidence from those with an intimate knowledge of the company..
Our perspective of the newest Annovis Bio gain
The recent surge in Annovis Bio's semi deviation of over 13.06 is a significant development for investors. This increase suggests a potential upward trend in the stock's volatility, indicating both higher risk and potential for high returns. This could be an opportune moment for risk-tolerant investors to invest in Annovis Bio. The company's large volatility of returns over the selected time horizon requires understanding of market volatility trends for effective timing. Using volatility indicators properly can help measure Annovis Bio's stock risk against market volatility during both bullish and bearish trends. The heightened volatility in bear markets can impact Annovis Bio's stock price and stress investors as they see their shares' value decrease, often prompting portfolio rebalancing with different financial instruments.In conclusion, Annovis Bio, Inc.
is a promising investment opportunity, particularly for those interested in the biotech sector. The company's lead product candidate, Buntanetap, has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative diseases. This, along with the development of ANVS405 and ANVS301, demonstrates the company's commitment to addressing significant medical needs. The analyst overall consensus is a 'Buy', with a possible upside price of $17.53 and a highest estimated target price of
$51.06. However, investors should also consider the possible downside price of $0.0677. The company's valuation market value stands at $6.77, while its real value is estimated at
$16.26. Given these factors, Annovis Bio presents a potentially profitable investment opportunity, but as with all investments, it is crucial to conduct thorough research and consider the inherent risks..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Annovis Bio. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com